1.Male or Female subjects of age 18-65 years (both inclusive) <br/ >2.Subjects with documented laboratory confirmed COVID-19 infection with positive qualitative reverse transcriptaseâ??polymerase chain reaction (RT-PCR) <br/ >3.Criteria for diagnosis of moderate COVID disease - Pneumonia with presence of clinical features of dyspnea and or hypoxia, fever, cough, including SpO2 <93% (range 90-93%) on room air, Respiratory Rate more or equal to 24-30 per minute OR on low flow oxygen (up to 6 litres per minute to maintain saturation above 93%) <br/ >4.For female subjects: evidence of post-menopause, or, for pre-menopause subjects, negative serum pregnancy test <br/ >5.Eligible subjects of child-bearing age (male or female) must agree to take effective contraceptive measures (including hormonal contraception, barrier methods or abstinence) with his/her partner during the trial period and for at least 30 days following the last day of trial treatment administered. <br/ >6.Not participating in any other interventional drug clinical studies before completion of the present trial <br/ >7.Subjects with ability to understand and provide written informed consent form, which must have been obtained prior to screening. <br/ >8.Subjects willing to comply with the protocol requirements. <br/ >

1.Male or Female subjects of age 18-65 years (both inclusive) <br/ >2.Subjects with documented laboratory confirmed COVID-19 infection with positive qualitative reverse transcriptaseâ??polymerase chain reaction (RT-PCR) <br/ >3.Criteria for diagnosis of moderate COVID disease - Pneumonia with presence of clinical features of dyspnea and or hypoxia, fever, cough, including SpO2 <93% (range 90-93%) on room air, Respiratory Rate more or equal to 24-30 per minute OR on low flow oxygen (up to 6 litres per minute to maintain saturation above 93%) <br/ >4.For female subjects: evidence of post-menopause, or, for pre-menopause subjects, negative serum pregnancy test <br/ >5.Eligible subjects of child-bearing age (male or female) must agree to take effective contraceptive measures (including hormonal contraception, barrier methods or abstinence) with his/her partner during the trial period and for at least 30 days following the last day of trial treatment administered. <br/ >6.Not participating in any other interventional drug clinical studies before completion of the present trial <br/ >7.Subjects with ability to understand and provide written informed consent form, which must have been obtained prior to screening. <br/ >8.Subjects willing to comply with the protocol requirements. <br/ >

1.Male or Female subjects of age 18-65 years (both inclusive) <br/ >2.Subjects with documented laboratory confirmed COVID-19 infection with positive qualitative reverse transcriptaseâ??polymerase chain reaction (RT-PCR) <br/ >3.Criteria for diagnosis of moderate COVID disease - Pneumonia with presence of clinical features of dyspnea and or hypoxia, fever, cough, including SpO2 <93% (range 90-93%) on room air, Respiratory Rate more or equal to 24-30 per minute OR on low flow oxygen (up to 6 litres per minute to maintain saturation above 93%) <br/ >4.For female subjects: evidence of post-menopause, or, for pre-menopause subjects, negative serum pregnancy test <br/ >5.Eligible subjects of child-bearing age (male or female) must agree to take effective contraceptive measures (including hormonal contraception, barrier methods or abstinence) with his/her partner during the trial period and for at least 30 days following the last day of trial treatment administered. <br/ >6.Not participating in any other interventional drug clinical studies before completion of the present trial <br/ >7.Subjects with ability to understand and provide written informed consent form, which must have been obtained prior to screening. <br/ >8.Subjects willing to comply with the protocol requirements. <br/ >

1.Male or Female subjects of age 18-65 years (both inclusive) <br/ >2.Subjects with documented laboratory confirmed COVID-19 infection with positive qualitative reverse transcriptaseâ??polymerase chain reaction (RT-PCR) <br/ >3.Criteria for diagnosis of moderate COVID disease - Pneumonia with presence of clinical features of dyspnea and or hypoxia, fever, cough, including SpO2 <93% (range 90-93%) on room air, Respiratory Rate more or equal to 24-30 per minute OR on low flow oxygen (up to 6 litres per minute to maintain saturation above 93%) <br/ >4.For female subjects: evidence of post-menopause, or, for pre-menopause subjects, negative serum pregnancy test <br/ >5.Eligible subjects of child-bearing age (male or female) must agree to take effective contraceptive measures (including hormonal contraception, barrier methods or abstinence) with his/her partner during the trial period and for at least 30 days following the last day of trial treatment administered. <br/ >6.Not participating in any other interventional drug clinical studies before completion of the present trial <br/ >7.Subjects with ability to understand and provide written informed consent form, which must have been obtained prior to screening. <br/ >8.Subjects willing to comply with the protocol requirements. <br/ >